Clinical Trial Update: Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial [Phase 2]

View source ↗

Summary

Phase 2 pediatric MATCH trial results for Tipifarnib in HRAS-altered solid tumors and histiocytic disorders; the study has posted results and is currently not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Langerhans Cell Histiocytosis
• Malignant Glioma
• Medulloblastoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma
• Wilms Tumor

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-03